BioAdvance - Articles
Newsroom >> BioAdvance and Regional News

Today’s Top Regional Life Sciences Stories from Business Wire

NPS Pharmaceuticals to Present at Upcoming Conferences
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the 14th Annual Bio CEO and Investor Conference in New York on Monday, February 13, 2012 at 9:30 a.m. ET and the Leerink Swann Global Healthcare Conference on Thursday, February 16, 2012 at 9:00 a.m. ET. Presentations will be available as live webcasts with replays available approximately three hours after the presentations have concluded. Interested parties may access the webcast from the inve
ALung Technologies Raises $10 Million in Series B Financing
PITTSBURGH--(BUSINESS WIRE)--ALung Technologies has secured additional financing to support the commercialization of its Hemolung Respiratory Assist System, a new medical device for providing extracorporeal CO2 removal.
Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if approved, will be a new mechanism for the treatment of insomnia. The two pivotal Phase III efficacy trials for suvorexant have been completed and, based on the positive results of these studies, Merck plans to file a New Drug Application (NDA) for suvo
SDIX Announces Collaboration Agreement with BD Diagnostics
NEWARK, Del.--(BUSINESS WIRE)--SDIX (NASDAQ: SDIX), a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic and food safety applications, and BD Diagnostics, a segment of BD (Becton Dickinson and Company), a leading global medical technology company, today announced the signing of a comprehensive agreement whereby the two companies will collaborate in the development of a microbiology detection solution. The collaboration will
SAFE-BioPharma® Standard to be Highlighted at Molecular TriCon
FORT LEE, N.J.--(BUSINESS WIRE)--SAFE-BioPharma interoperable digital identities in assuring secure cloud computing will be featured at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference
Incyte to Present at the Leerink Swann 2012 Global Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announced today it will present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012 at 2:30 p.m. (ET) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 90 days. Investors interested in listening to the live webcast should log on before the start time in order t
Teleflex to Focus on Innovative Products at the Society of Critical Care Medicine’s 41st Critical Care Congress
LIMERICK, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) will showcase a number of anesthesia, respiratory therapy and vascular access products at the Society of Critical Care Medicine’s 41st Critical Care Congress February 4-8, in Houston, Texas. Teleflex will highlight: The Teleflex ISIS® HVT™, the first convertible endotracheal tube, features an integrated suction port and separate suction line allowing for subglottic secretion suctioning on demand. Now clinicians can be free from th
OptiNose Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery Technology
YARDLEY, Pa.--(BUSINESS WIRE)--OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology. “This filing signals an important milestone in our quest to deliver improved relief to p
Regulatory Harmonization Institute and Korea Health Industry Development Institute Partner to Launch 2012 Columbus Project
ELMWOOD PARK, N.J.--(BUSINESS WIRE)--The Regulatory Harmonization Institute, Inc. (RHI) an international, not-for-profit association dedicated to global harmonization of drug and medical device regulatory requirements, and the Korea Health Industry Development Institute (KHIDI), the Korean government organization, announced today to partner in support of the 2012 Columbus Project, a Korean government program to boost globalization of Korea’s healthcare industry. KHIDI has enrolled 42 Korean manu
Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2011.     $ in millions, except EPS amounts   FourthQuarter2011   FourthQuarter2010   Year EndedDec. 31,2011   Year EndedDec. 31,2010 Sales   $12,294   $12,094   $48,047   $45,987 GAAP EPS   0.49   (0.17)   2.02   0.28 Non-GAAP EPS that excludes items listed below1   0.97   0.88   3.77   3.42 GAAP Net Income (Lo